

2020 American Academy of Neurology Parkinson's Disease (PD) Measurement Set

QM 1 ANNUAL PARKINSON'S DISEASE DIAGNOSIS REVIEW		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who had their diagnosis reviewed annually for the first 5 years after initial diagnosis of PD	All patients with a diagnosis of PD	None

QM 2 CONTRAINDICATED DOPAMINE-BLOCKING MEDICATIONS		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients currently prescribed a contraindicated dopamine-blocking agent	All patients with a diagnosis of PD	Patients taking clozapine or quetiapine or domperidone

QM 3 ASSESSMENT OF PARKINSON'S DISEASE MEDICATION-RELATED MOTOR COMPLICATIONS		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were assessed for dopaminergic medication-related motor complications once during the measurement period	All patients with a diagnosis of PD on a dopaminergic medication	Patients who are not able to participate in assessment and no knowledgeable informant available

QM 4 PARKINSON'S DISEASE REHABILITATIVE THERAPY REFERRAL		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were referred to physical, occupational, speech, or recreational therapy once during the measurement period	All patients with a diagnosis of PD	Patients and/or care partners decline referral; Clinician determines patient does not require referral; Patients already receiving physical, occupational, speech, or recreational therapy during the measurement period

QM 5 EXERCISE OR PHYSICAL ACTIVITY COUNSELING		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients counseled on an exercise or physical activity regimen once during the measurement period	All patients with a diagnosis of PD	Patients and/or care partners decline counseling; Comorbid condition that deems the patient unfit to participate in physical activity; Patients who are not able to participate in counseling and no knowledgeable informant available

2020 American Academy of Neurology Parkinson's Disease (PD) Measurement Set

QM 6 ASSESSMENT OF MOOD DISORDERS AND PSYCHOSIS		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were assessed for depression, anxiety, apathy, and psychosis once during the measurement period	All patients with a diagnosis of PD	None

QM 7 ASSESSMENT OF IMPULSE CONTROL DISORDERS		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were assessed for impulse control disorder once during the measurement period	All patients with a diagnosis of PD currently taking medications for PD	None

QM 8 ASSESSMENT OF SLEEP DISTURBANCES		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were assessed for sleep disturbances once in the past 12 mo	All patients with a diagnosis of PD	None

QM 9 ASSESSMENT OF COGNITIVE IMPAIRMENT OR DYSFUNCTION		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were assessed for cognitive impairment or dysfunction once in the past 12 mo	All patients with a diagnosis of PD	Patients and/or care partners decline assessment; Patients who are not able to participate in assessment and no knowledgeable informant available

QM 10 ASSESSMENT OF AUTONOMIC DYSFUNCTION		
NUMERATOR	DENOMINATOR	EXCLUSION
Patients who were assessed for symptoms or signs of autonomic dysfunction once in the past 12 mo	All patients with a diagnosis of PD	None

Chou, K. L., Martello, J., Atem, J., Elrod, M., Foster, E. R., Freshwater, K., Gunzler, S. A., Kim, H., Mahajan, A., Sarva, H., Stebbins, G. T., Lee, E., & Yang, L. (2020). Parkinson's Disease Quality Measure Set 2020 Update. American Academy of Neurology.